Compare ARK Genomic Revolution ETF (ARKG) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Standard Lithium Ltd — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Standard Lithium Ltd trades at $2.45 (market cap $602.91M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | SLI | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $5.65 |
52-Week Low | $23.09 | $2.29 |
Market Cap | — | $602.91M |
Enterprise Value | — | $462.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Standard Lithium (SLI) trades at $2.46, down 3.15% today, showing bearish technical momentum despite unanimous analyst buy ratings. The company reported negative earnings with Q1 2026 beating expectations but Q4 2025 missing. Strong financing activities of $163.58M in 2025 support development of the South West Arkansas lithium project, with major operational milestones achieved at the demonstration plant.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include negative cash flow from operations and high capital expenditures, but the $225M DOE grant and strategic partnerships provide funding stability. Analyst consensus remains strongly bullish with 100% buy ratings, viewing current weakness as a buying opportunity for long-term lithium exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
